Erasca, Inc. Q1 2025 10-Q: New License Agreements
Ticker: ERAS · Form: 10-Q · Filed: May 13, 2025 · CIK: 1761918
Sentiment: neutral
Topics: 10-Q, licensing-agreement, pharmaceuticals
TL;DR
Erasca inks new deals with Medshine & Joyo, Q1 2025 10-Q out.
AI Summary
Erasca, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business activities. Key events include license agreements with Medshine Discovery Inc. and Guangzhou Joyo Pharmatech Co., Ltd., both effective January 1, 2025, and a license agreement with NiKang Therapeutics Incorporation initiated on April 1, 2020.
Why It Matters
This filing provides insight into Erasca's strategic partnerships and potential future revenue streams through its various license agreements, which are crucial for its drug development pipeline.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical development stage, which inherently carries significant risks related to clinical trials, regulatory approvals, and market adoption.
Key Numbers
- N/A — Revenue (Specific revenue figures for the quarter are not detailed in the provided text.)
- N/A — Net Income/Loss (Specific net income or loss figures for the quarter are not detailed in the provided text.)
- N/A — Cash and Equivalents (Specific cash and equivalents figures for the quarter are not detailed in the provided text.)
Key Players & Entities
- Erasca, Inc. (company) — Filer of the 10-Q
- Medshine Discovery Inc. (company) — Party to a license agreement
- Guangzhou Joyo Pharmatech Co., Ltd. (company) — Party to a license agreement
- NiKang Therapeutics Incorporation (company) — Party to a license agreement
- 20250331 (date) — End of reporting period
- 20250513 (date) — Filing date
FAQ
What is the effective date of the license agreement with Medshine Discovery Inc.?
The license agreement with Medshine Discovery Inc. is effective as of January 1, 2025.
When was the license agreement with Guangzhou Joyo Pharmatech Co., Ltd. initiated?
The license agreement with Guangzhou Joyo Pharmatech Co., Ltd. is effective as of January 1, 2025.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 13, 2025.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was the license agreement with NiKang Therapeutics Incorporation initiated?
The license agreement with NiKang Therapeutics Incorporation was initiated on April 1, 2020.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Erasca, Inc. (ERAS).